Oliver Schacht, PhD, is a well-known expert in the diagnostics industry with a distinguished career at Epigenomics AG. He served as CFO of Epigenomics AG (Berlin, Germany) and as CEO for Epigenomics, Inc. (Seattle, USA). He has an extensive track record in strategy development and implementation, fund-raising (including IPO), finance, M&A and alliance negotiation. Oliver Schacht holds a diploma in European Business Administration from the European School of Business in Reutlingen and London, as well as a Master’s and Ph.D. degree from the University of Cambridge (UK). During his tenure at Mercer Management Consulting, he worked on projects in M&A, growth strategies and reorganization in pharmaceutical, biotechnology, and other sectors. To Curetis, he brings background in the molecular diagnostics industry from technology development, through discovery and clinical validation, to the market launch of molecular tests.

With 25 years of professional experience at Hewlett Packard and other major medical device companies, Andreas Boos has a proven, international track record in developing and implementing solutions in patient monitoring and in molecular and point-of-care diagnostics. With a degree in electrical engineering, Andreas has successfully applied project and program management skills to lead the development of several innovative and commercially successful medical products for the worldwide market. Next to an intimate understanding of the customer's needs, he also brings a thorough knowledge of applicable quality systems, standards, and the regulatory approval processes to Curetis.

With a degree in electrical engineering, Johannes Bacher has worked for
several international medical device companies, such as Hewlett Packard
and Philips Medical Systems. He combines more than 15 years of R&D and
management experience with a strong background in international project
management, finance, and setting up organizational structures, which puts him in a good position to manage Curetis' operations.

Gerd Lüdke has more than 20 years of experience in assay development
for research and for analytical and diagnostic systems, and has experience
in managing international multisite projects. He was responsible for
molecular diagnostic assay design and developing clinical tests at Philips
Medical Systems, and worked as project manager for microfluidic systems
at Agilent Technologies before joining Curetis. Gerd has a doctorate in
Cancer Biology (University Hospital in Zurich, Switzerland) and a degree in
Technical Biology (University of Stuttgart, Germany).

Before joining Curetis, Anne Thews was Marketing Manager at Philips
Medical Systems. She previously held leading marketing and sales support
positions at Beckman Coulter. She has achieved an impressive track record
during the past 20 years both in strategic and tactical marketing, and is
well recognized in the relevant professional and academia networks. Her
combined professional experience as a marketing specialist with
international responsibilities, as a trained medical doctor (Internal
Medicine), and as manager in charge of a clinical diagnostics laboratory for
many years (University Hospital Mainz, Germany) make her a valuable
asset to Curetis.

Anne Burger is a Director at MedVenture Partners, a Munich based
corporate finance and strategic advisory company focusing on the life
sciences and healthcare industry. At MedVenture Partners, Anne has been
responsible for many projects in private placements, financial modelling
and M&A. She has worked for companies across many segments in
biotechnology, pharmaceutical services (CRO), medical devices, medical
telemonitoring, hospital service providers, and healthcare IT. She holds a
graduate degree in business administration (Ludwig-Maximilian-Universität
Munich, Honours) and did graduate studies in public health. Anne is a
regular lecturer at the Odeon Centre for Entrepreneurship of the Ludwig-
Maximilian-Universität Munich.

Dr. Klaus Brinkmann joined Curetis as our Director Sales in November 2011 after 15 years in the in-vitro diagnostics industry in senior commercial management roles. He has an outstanding track record in commercialization of complex IVD products (instrument platforms as well as test kits) in the area of immunology, traditional microbiology, as well of molecular-based infectious disease testing.  In several sales positions of growing responsibility at Beckman Coulter, Becton Dickinson and Bio-Rad he has gained extensive expertise is setting-up commercial infrastructures and leading sales teams in very competitive markets ensuring commercial success. His strong customer network is a valuable addition to the Curetis team. Klaus Brinkmann studied chemistry and holds a doctorate of the University Giessen.